Sun Pharmaceutical Industries said in a filing to BSE. The drug has been developed by InSite Vision which the company had acquired in November 2015, it added. The company is likely to commercialise BromSite through its newly formed US-based division Sun Ophthalmics in the second half of 2016, it said. "As per IMS MAT January 2016, the US NSAID ophthalmic market grew by 8 percent, generating approximately USD 400 million in sales and about 4 million prescriptions, providing an attractive market for Sun.
As per the USFDA, NDA application is the vehicle through which drug sponsors formally propose that the FDA approve a new pharmaceutical for sale and marketing in the US.
Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's largest drug maker.